# US 2003/0223935 A1 · Fluorescent membrane intercalating probes and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223935 A1
- Document ID: US20030223935A1
- Status: Published application
- Kind: A1
- Application number: 10/220,241
- Filed: 2002-11-01
- Published: 2003-12-04
- Earliest claimed: 2002-11-01
- Inventors: Brian D. Gray
- Web page: https://patentgrep.com/patent/US20030223935A1

## CPC

- A61K 49/0097: {Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo}
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a family of cyanine dyes which fluoresce in the far red and near infra red wavelengths of the spectrum and preferably possess lipophilic side chains. The dyes of the invention are soluble in commercially available membrane staining vehicles, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well retained therein. Methods of using the dyes to detect stained cells both in vivo and in vitro are also disclosed.

## Claims

### Claim 1

An in vivo method for detecting abnormal cell shedding rates of mature surface epithelial cells of a warm blooded animal, comprising the steps of:
labeling mature surface epithelial cells at a target site of the animal with a cyanine dye, and monitoring the site for the presence or absence of the label following said labeling step, wherein the cyanine dye is of the formula
12
wherein
“—Y═”
is selected from the group consisting of
—CR5═, —CR6═CR7—CR8═, —CR9═CR10—CR11═CR12—CR13═
, and
13
wherein each of R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, and R13 is independently H, halogen or an alkyl group of 1-4 carbons;
X is selected from the group consisting of H, halogen, O-alkyl, O-aryl, S-alkyl and S-aryl;
Z is a biologically compatible counterion;
“A-”
is a structure selected from the group of structures consisting of
14
and “=B” is selected from the group consisting of
15
wherein D and E are each independently O, S or CR14R15, where R14 and R15, which may be the same or different, are independently alkyl groups having 1-4 carbons or R14R15 taken in combination complete a 5- or 6-membered saturated ring;
R and R′ each independently linear or branched hydrocarbons having 7-30 carbons, with the provisos that (i) one of R and R′ must be at least 14 carbons and (ii) R≠R′; and
each of R16-R47 is independently H, halogen or an alkyl group of 1-4 carbons.

### Claim 2 (depends on 1)

A method as in claim 1 wherein the cyanine dye is selected from the group consisting of
16

### Claim 3

A compound having the structural formula
17

### Claim 4

A compound having the structural formula
18

### Claim 5

A compound having the structural formula
19

### Claim 6

A compound having the structural formula
20

### Claim 7

A compound having the structural formula
21

### Claim 8

A compound having the structural formula
22

### Claim 9

A compound having the structural formula
23

### Claim 10

An in vivo method for detecting abnormal cell shedding rates of mature surface epithelial cells of a warm-blooded animal, comprising the steps of:
labeling mature surface epithelial cells at a target site of the animal with a cyanine dye;
exciting the target site with a light source; and
monitoring the site for the presence of absence of fluorescence resulting therefrom;
wherein the cyanine dye is of the formula
24
wherein
“—Y═”
is selected from the group consisting of
—CR5═, —CR6═CR7—CR8═, —CR9═CR10—CR11═CR12—CR13═
, and
25
wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is independently H, halogen or an alkyl group of 1-4 carbons;
X is selected from the group consisting of H, halogen, O-alkyl, O-aryl, S-alkyl and S-aryl;
Z is a biologically compatible counterion;
“A-”
is a structure selected from the group of structures consisting of
26
and “=B” is selected from the group consisting of
27
wherein D and E are each independently O, S or CR14R15, where R14 and R15, which may be the same or different, are independently alkyl groups having 1-4 carbons or R14R15 taken in combination complete a 5- or 6-membered saturated ring;
R and R′ each independently linear or branched hydrocarbons having 7-30 carbons, with the provisos that (i) one of R and R′ must be at least 14 carbons and (ii) R≠R′; and
each of R16-R47 is independently H, halogen or an alkyl group of 1-4 carbons.

### Claim 11 (depends on 10)

The method of claim 10 wherein the site is a mucosal surface.

### Claim 12 (depends on 11)

The method of claim 11 wherein the mucosal surface lines the surface of the gastrointestinal tract, the respiratory tract, or the genitourinary tract.

### Claim 13 (depends on 11)

The method of claim 11 wherein the site is a mucosal surface of the stomach.

### Claim 14 (depends on 11)

The method of claim 11 wherein the site is a mucosal surface of the colon.

### Claim 15 (depends on 10)

The method of claim 10 wherein cell shedding is detected by observing changes in the level of the label at the site at a pre-selected time following said labeling step.

### Claim 16 (depends on 10)

The method of claim 10 wherein the excitation light has a wavelength of from about 600 nm to about 900 nm.

### Claim 17 (depends on 10)

The method of claim 10 wherein the epithelial cells are labeled by direct application of a labeling composition to the site.

### Claim 18

A method for labeling a cell, comprising the steps of:
contacting the cell with a labeling composition of the formula
28
wherein
“—Y═”
is selected from the group consisting of
CR5═, —CR6═CR7—CR8═, —CR9═CR10—CR11═CR12—CR13═
, and
29
wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is independently H, halogen or an alkyl group of 1-4 carbons;
X is selected from the group consisting of H, halogen, O-alkyl, O-aryl, S-alkyl and S-aryl;
Z is a biologically compatible counterion;
“A-”
is a structure selected from the group of structures consisting of
30
and “=B” is selected from the group consisting of
31
wherein D and E are each independently O, S or CR14R15, where R14 and R15, which may be the same or different, are independently alkyl groups having 1-4 carbons or R14R15 taken in combination complete a 5- or 6-membered saturated ring;
R and R′ each independently linear or branched hydrocarbons having 7-30 carbons, with the provisos that (i) one of R and R′ must be at least 14 carbons and (ii) R≠R′; and
each of R16-R47 is independently H, halogen or an alkyl group of 1-4 carbons.

### Claim 19 (depends on 18)

The method according to claim 18 wherein said labeling composition comprises a pharmaceutically acceptable vehicle.
